Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancerBhuvaneswari Ramaswamy, William E. Carson, Maryam B. Lustberg et al.|Cancer Research|2016Cited by 15